E7386

Oncology (undisclosed)

Phase 1Active (Co-created with Eisai, clinical results published)

Key Facts

Indication

Oncology (undisclosed)

Phase

Phase 1

Status

Active (Co-created with Eisai, clinical results published)

Company

PRISM BioLab develops peptide-mimetic small molecules to drug challenging protein-protein interactions using its proprietary PepMetics® platform.

Drug	Company	Phase	Status
CLD-601	Calidi Biotherapeutics	Discovery	Active
Protease Inhibitor Discovery Programs	Medivir	Discovery	Active
Nucleoside/Nucleotide Discovery Programs	Medivir	Discovery	Active
Orion Collaboration Program 1	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 2	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 3	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 4-6 (Extended)	Glykos Finland	Research	Active
NEX-20	Nanexa	Preclinical	Active
NEX-18	Nanexa	Preclinical	Active
ISB 830	Glenmark Pharmaceuticals	Preclinical	Active
TEM-1	Tempus AI	Discovery/Preclinical	Active
TEM-2	Tempus AI	Discovery/Preclinical	Active